Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients

Br J Plast Surg. 2000 Oct;53(7):559-62. doi: 10.1054/bjps.2000.3409.

Abstract

A consecutive cohort of 100 patients who had undergone sentinel lymph node biopsy (SLNB) was analysed retrospectively. Three areas were studied: success in finding the sentinel node(s); complications of the procedure; and extra costs incurred by SLNB. The sentinel node(s) were successfully identified in 98% of the lymph node basins biopsied. The overall complication rate was 33%. The additional cost of the procedure was estimated at 1420 pounds sterling per patient. SLNB can reliably identify the sentinel node. However there is a significant complication rate of the technique and considerable additional costs. SLNB requires further critical evaluation before it can be accepted as a standard treatment for patients with malignant melanoma.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Health Care Costs
  • Hematoma / etiology
  • Humans
  • Lymphatic Metastasis
  • Male
  • Melanoma / pathology
  • Melanoma / secondary*
  • Middle Aged
  • Retrospective Studies
  • Sentinel Lymph Node Biopsy* / adverse effects
  • Sentinel Lymph Node Biopsy* / economics
  • Skin Neoplasms / pathology*
  • Surgical Wound Infection / etiology